Christian Capitini
Contact Information
ccapitini@pediatrics.wisc.edu
608-262-2415
Education
BA, Drew University, Madison, New Jersey
MD, Rochester School of Medicine and Dentistry, Rochester, New York
Residency, Pediatrics, University of Minnesota, Minneapolis, Minnesota
Fellowship, Pediatric Hematology and Oncology, Johns Hopkins University, National Cancer Institute, Baltimore and Bethesda, Maryland
Fellowship, Pediatric Oncology and Immunology Section, National Cancer Institute, Bethesda, Maryland
Title
Professor of Pediatrics, School of Medicine and Public Health
Director, University of Wisconsin Carbone Cancer Center
Research Description
Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based therapies, including NK cells and CAR T cells, for the treatment of childhood cancers like neuroblastoma and osteosarcoma. The laboratory also manufactures alternatively activated macrophages for complications of hematopoietic stem cell transplant, like graft-versus-host-disease and acute radiation syndrome. In the clinic, Dr. Capitini was a site Principal Investigator for the first multi-center CAR T cell trial, which led to FDA approval of tisagenlecleucel (Kymriah) for the treatment of recurrent/refractory B cell leukemia in children. He remains a site PI for trials testing Kymriah as upfront therapy for high risk B cell leukemias and for treatment of relapsed non-Hodgkin lymphoma.